MARSEILLE, France--(BUSINESS WIRE)--Sep 17, 2025--

Regulatory News:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today reported its consolidated financial results for the six months ended June 30, 2025 . The consolidated financial statements are attached to this press release.

“ With key milestones anticipated over the next 12 months, our primary focus will be on progressing what we believe are our most promising and highest-value clinical assets and advancing our next ADCs toward development. In line with this strategic focus and in a challenging funding environment, we are taking necessary action to focus our resources on what we believe are the programs with the highest potential to deliver value for both patients and shareholders, and

See Full Page